Vimarsana
Biggest News Aggregation in the World

Nanoparticle Delivery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nanoparticle Delivery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nanoparticle Delivery Today - Breaking & Trending Today

Nanoparticle Delivery at "Cellular Level" to Advance Nanomedicine - Vimarsana News

Nanoparticle Delivery at "Cellular Level" to Advance Nanomedicine

An analytical method that helped study the distribution of nanoparticle delivery systems at the cellular level was developed to advance nanomedicine.

Employing Synergistic Strategies to Advance Nanomedicine - Vimarsana News

Employing Synergistic Strategies to Advance Nanomedicine

To advance nanomedicine, researchers will need to overcome the barrier that prevents clinical applications of nanomaterial systems.

Preclinical data show potential for Genprex's nanoparticle delivery system - Vimarsana News

Preclinical data show potential for Genprex's nanoparticle delivery system

Preclinical data show potential for use of Genprex's Oncoprex nanoparticle delivery system in treating colon cancer.

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting - Vimarsana News

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting News provided by Share this article Share this article SAN DIEGO, April 27, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced three data presentations to be delivered at the upcoming American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, being held virtually May 11-14, 2021. Poseida ...